Table 2.
Characteristics of patients with active disease at the time of sampling
| Patient number | Age (years) | ANCA type | Disease duration (months) | Disease activity at time of sampling | BVAS | CRP (mg/L) |
|---|---|---|---|---|---|---|
| 1 | 55 | PR3 | 0 | A, ENT, K, L | 25 | 292 |
| 2 | 37 | PR3 | 44 | A, ENT | 5 | 20 |
| 3 | 55 | PR3 | 57 | A, K, L | 15 | 247 |
| 4 | 58 | MPO | 120 | A, L | 7 | 23 |
| 5 | 49 | PR3 | 190 | A, ENT, L | 10 | 46 |
| 6 | 57 | PR3 | 259 | Ey, ENT | 6 | < 5 |
| 7 | 56 | PR3 | 191 | Ey | 6 | < 5 |
| 8 | 82 | MPO | 0 | L | 4 | 44 |
| 9 | 53 | PR3 | 0 | A, ENT, K, L | 17 | 160 |
| 10 | 74 | PR3 | 0 | K | 10 | NA |
| 11 | 69 | PR3 | 9 | ENT, K | 14 | 211 |
| 12 | 41 | MPO | 0 | A, ENT, K, S | 17 | 44 |
| 13 | 58 | MPO | 0 | ENT, K, S | 14 | 116 |
| 14 | 70 | MPO | 0 | A, ENT, K, L | 19 | 188 |
| 15 | 53 | PR3 | 15 | Ey, K | 12 | 12 |
| 16 | 24 | PR3 | 9 | A, Ey | 3 | 16 |
| 17 | 40 | MPO | 33 | ENT | 6 | < 5 |
| 18 | 41 | MPO | 284 | K, L | 12 | < 5 |
None of the patients received induction therapy at the time of sampling. PR3/MPO, proteinase-3/myeloperoxidase; this reflects anti-neutrophil-cytoplasmic antibodies specificity (ANCA) at the time of diagnosis. Organ involvement of patients with active disease at the time of sampling is depicted. A, arthritis (joints); BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; ENT, ear-nose-throat; Ey, ophthalmologic manifestation of disease; K, kidney; L, lung; S, skin.